Skip to content
PICO Portalanswers from OpenAlex

IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing

PaperCitations, authors & open-access status

IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing is a paper indexed in PICO Portal from OpenAlex.

How many citations does IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing have?

PICO Portalcitation count

IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing has 52 citations in the OpenAlex counts PICO Portal stores.

When was IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing published?

PICO Portalyear

IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing has 2023 year in the PICO Portal index.

What is the open-access status of IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing?

PICO Portaloa status

IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing has hybrid oa status in the PICO Portal index.

What is the DOI of IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing?

PICO Portaldoi

The DOI for IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing is on the source record.

What is the PMID of IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing?

PICO Portalpmid

The PMID for IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing is on the source record.

What is the OpenAlex record for IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing?

PICO Portalopenalex

The OpenAlex for IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial